Advancing Precision Medicine with Companion Diagnostics and Biomarkers https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period. Growth in this market is mainly driven by factors such as the high drug development activity, structured regulatory framework in the region, large patient pool undergoing advanced medical testing, and policy programs to provide effective care to patients with cancer.

Companion Diagnostics: Revolutionizing Personalized Medicine https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period. Growth in this market is mainly driven by factors such as the high drug development activity, structured regulatory framework in the region, large patient pool undergoing advanced medical testing, and policy programs to provide effective care to patients with cancer. The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Exploring the Growing Market for Companion Diagnostics: Trends and Forecast https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period. Growth in this market is mainly driven by factors such as the high drug development activity, structured regulatory framework in the region, large patient pool undergoing advanced medical testing, and policy programs to provide effective care to patients with cancer. The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).